Sotera Health Company Common Stock (SHC)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Sotera as a necessary-but-levered healthcare service provider. Its Sterigenics, Nordion, and Nelson Labs segments perform sterilization, irradiation, and lab testing that medical customers cannot easily skip. That can create sticky demand, but the figures show a business still proving itself. Filed revenue rose from $1.0B in fiscal year 2023, the year ended 2023-12-31, to $1.2B in fiscal year 2025, the year ended 2025-12-31, and net income moved from $44.4M in fiscal year 2024, the year ended 2024-12-31, to $77.9M in fiscal year 2025, the year ended 2025-12-31. The latest inflection is striking: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $321.4M, net income was $53.6M, and diluted EPS was $0.19, versus net income of $8.0M and EPS of $0.03 in fiscal Q2 2025, the quarter ended 2025-06-30.

In plain English: Sotera Health helps medical companies sterilize equipment and run safety tests. The business is improving: sales and profits have grown, and the latest quarter showed much higher profit than a year earlier. But the company owes a lot of money and produces little spare cash compared with its stock market value, so at the recent price of $18.21 the stock looks expensive rather than cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer